

# Massar Omar

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7005507/massar-omar-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

138  
citations

6  
h-index

11  
g-index

17  
ext. papers

299  
ext. citations

8.2  
avg, IF

2.84  
L-index

#	Paper	IF	Citations
14	Reply: Accelerometers: A Useful Technology in HF Research?. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 70-71	7.9	
13	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 34	8.7	0
12	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial.. <i>American Heart Journal</i> , <b>2022</b> , 250, 57-57	4.9	
11	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis from the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> ,	7.6	3
10	Cardiovascular autonomic neuropathy in patients with schizophrenia. <i>Nordic Journal of Psychiatry</i> , <b>2021</b> , 75, 547-552	2.3	
9	Fluid volume regulation in patients with heart failure - Authorscreply. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 258	18.1	
8	Response to Patoulis et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial". <i>American Heart Journal</i> , <b>2021</b> , 236, 106	4.9	
7	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , <b>2021</b> , 143, 2208-2210	16.7	2
6	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 106-114	18.1	35
5	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 836-840	16.2	24
4	Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 824-835	7.9	1
3	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , <b>2020</b> , 228, 47-56	4.9	25
2	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2740-2751	15.1	21
1	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). <i>Trials</i> , <b>2019</b> , 20, 374	2.8	21